Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Faranak Aghaei
Observed institutions:
Roche (United States),
St James's University Hospital,
Wellcome Trust
ORCID:
0009-0000-6076-5978
Observed ORCID:
0009-0000-6076-5978
OpenAlex ID:
A5004579366
Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial
2024
·
Christopher J.M. Williams
, Richard Gray
, et al.
·
Journal of Clinical Oncology
·
28
Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2023
·
Christopher J.M. Williams
, Faye Elliott
, et al.
·
Clinical Cancer Research
·
23
PDF
Artificial intelligence-assisted evaluation of tumor infiltrating CD3+ and CD8+ T cells for prognostication and prediction of benefit from adjuvant chemotherapy in early stage colorectal cancer (CRC): A retrospective analysis of the QUASAR trial.
2023
·
Christopher Williams
, Richard G Gray
, et al.
·
Journal of Clinical Oncology
·
4
Supplementary Methods S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Table S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Figure S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Table S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Figure S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2025
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Figure S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Methods S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S3 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Table S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S2 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
2024
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Supplementary Figure S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2023
·
Christopher J.M. Williams
, Faye Elliott
, et al.
PDF
Supplementary Methods S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
2023
·
Christopher J.M. Williams
, Faye Elliott
, et al.
Show more works
View as search
Works count:
47
Citation count:
55
H-index:
3
I10-index:
2
Year
Topic
Type
